PROQR THERAPEUTICS EO-04 (0PQ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PROQR THERAPEUTICS EO-04 (0PQ) has a cash flow conversion efficiency ratio of -0.271x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-13.36 Million ≈ $-15.62 Million USD) by net assets (€49.37 Million ≈ $57.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PROQR THERAPEUTICS EO-04 (0PQ) balance sheet quality index to measure how much of total assets are equity-financed.
PROQR THERAPEUTICS EO-04 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how PROQR THERAPEUTICS EO-04's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PROQR THERAPEUTICS EO-04 total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
PROQR THERAPEUTICS EO-04 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PROQR THERAPEUTICS EO-04 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tung Thih Electronic Co Ltd
TWO:3552
|
0.091x |
|
S&P Syndicate Public Company Limited
BK:SNP
|
0.106x |
|
Hana Financial 7 SPAC
KQ:230240
|
-0.070x |
|
Major Cineplex Group Public Company Limited
BK:MAJOR
|
0.026x |
|
Calin Technology Co Ltd
TW:4976
|
-0.011x |
|
Tonlin Department Store Co Ltd
TW:2910
|
0.020x |
|
Asian Hotels (North) Limited
NSE:ASIANHOTNR
|
-0.675x |
|
Sungei Bagan Rubber Malaya
KLSE:2569
|
0.000x |
Annual Cash Flow Conversion Efficiency for PROQR THERAPEUTICS EO-04 (2021–2025)
The table below shows the annual cash flow conversion efficiency of PROQR THERAPEUTICS EO-04 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see 0PQ stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €49.37 Million ≈ $57.72 Million |
€-52.79 Million ≈ $-61.72 Million |
-1.069x | -160.18% |
| 2024-12-31 | €88.56 Million ≈ $103.54 Million |
€-36.39 Million ≈ $-42.55 Million |
-0.411x | -178.93% |
| 2023-12-31 | €41.39 Million ≈ $48.39 Million |
€21.55 Million ≈ $25.19 Million |
0.521x | +150.67% |
| 2022-12-31 | €66.68 Million ≈ $77.96 Million |
€-68.51 Million ≈ $-80.09 Million |
-1.027x | -347.22% |
| 2021-12-31 | €113.23 Million ≈ $132.38 Million |
€-26.01 Million ≈ $-30.41 Million |
-0.230x | -- |
About PROQR THERAPEUTICS EO-04
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more